Sammy Farah, Turnstone Biologics CEO
Turnstone charts $75M IPO for TIL cell therapies in drumroll of biotech IPOs this month
Turnstone Biologics plans to list on the Nasdaq in a $75 million raise shortly after a trio of biotechs — Apogee Therapeutics, Sagimet Biosciences and 60 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.